STOCK TITAN
  1. Home
  2. Sec-filings
  3. RCKT
  4. [Form 4] ROCKET PHARMACEUTICALS, INC. Insider Trading Activity

Rocket Pharmaceuticals (RCKT) director receives new RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Rocket Pharmaceuticals director Peter Fong received equity awards as part of his compensation. He was granted 22,862 restricted stock units that convert into common stock on a one-for-one basis and will vest in full on June 18, 2027. He also received a stock option to purchase 64,860 shares of common stock at an exercise price of $3.35 per share, which will become fully vested and exercisable on June 18, 2027 and will expire on June 18, 2036. Following the restricted stock unit grant, his direct common stock holdings reported in this filing total 76,195 shares.

Positive

  • None.

Negative

  • None.
Insider Fong Peter
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 64,860 $0.00 --
Grant/Award Common Stock 22,862 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 64,860 shares (Direct, null); Common Stock — 76,195 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
RSU grant size 22,862 RSUs Restricted stock units vesting June 18, 2027
Option grant size 64,860 options Stock option covering common shares
Option exercise price $3.35/share Exercise price for 64,860-share option
Option expiration June 18, 2036 Expiration date of stock option grant
RSU vesting date June 18, 2027 Full vesting date for 22,862 RSUs
Common shares after grant 76,195 shares Direct Rocket Pharmaceuticals common stock holdings
restricted stock units financial
"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of $3.35 per share."
exercise price financial
"This option represents a right to purchase a total of 64,860 shares ... with an exercise price of $3.35 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested and exercisable financial
"All of which will become fully vested and exercisable on June 18, 2027."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fong Peter
(Last)(First)(Middle)
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE
(Street)
CRANBURY NEW JERSEY 08512
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)06/18/2026A(2)22,862A$0(2)76,195D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$3.3506/18/2026A64,860 (2)06/18/2036Common Stock64,860$064,860D
Explanation of Responses:
1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
2. This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
/s/ Martin Wilson, as attorney-in-fact for Peter Fong07/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Peter Fong report at Rocket Pharmaceuticals (RCKT)?

Peter Fong reported receiving equity compensation awards, not open-market trades. He was granted restricted stock units and a stock option, both tied to Rocket Pharmaceuticals common stock, with future vesting and exercisability dates rather than immediate cash transactions.

How many Rocket Pharmaceuticals (RCKT) shares did Peter Fong receive through RSUs?

Peter Fong was granted 22,862 restricted stock units, each convertible into one share of Rocket Pharmaceuticals common stock. These RSUs vest in full on June 18, 2027, meaning he receives the underlying shares only when that vesting date is reached.

What are the details of Peter Fong’s stock option grant at Rocket Pharmaceuticals (RCKT)?

He received a stock option covering 64,860 shares of Rocket Pharmaceuticals common stock at an exercise price of $3.35 per share. The option becomes fully vested and exercisable on June 18, 2027 and is scheduled to expire on June 18, 2036 if not exercised earlier.

When do Peter Fong’s Rocket Pharmaceuticals (RCKT) RSUs and options vest?

Both the restricted stock units and the stock option grants vest in full on June 18, 2027. At that point, the RSUs convert one-for-one into common shares, and the option becomes fully exercisable at the stated $3.35 per share exercise price.

How many Rocket Pharmaceuticals (RCKT) shares does Peter Fong hold after these grants?

After the restricted stock unit grant, Peter Fong’s directly held Rocket Pharmaceuticals common stock reported in this filing totals 76,195 shares. This figure reflects his non-derivative holdings as of the transaction date stated in the Form 4.

Are Peter Fong’s Rocket Pharmaceuticals (RCKT) transactions open-market buys or compensation awards?

The reported transactions are compensation-related awards, not open-market purchases or sales. The Form 4 shows grants of restricted stock units and a stock option, both coded as acquisitions under a grant or award transaction type rather than discretionary market trading.